← ANALYST RATINGS · TIPRANKS
Zevra Therapeutics (ZVRA): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $25.25, the highest $35.00, the lowest $20.00. The average is +154.0% from the last price of $9.94.
Analyst ratings 9
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $11.00−4.3% | Buy | +10.7% | Upgrade | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $10.50−4.5% | Hold | +5.6% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 → $12.00−7.7% | Buy | +20.7% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 → $12.00−4.0% | Buy | +20.7% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 → $11.50−8.0% | Buy | +15.7% | Upgrade | 15.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $11.00−4.3% | Hold | +10.7% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 → $12.00−7.7% | Buy | +20.7% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $12.00−7.7% | Buy | +20.7% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 → $13.00+4.0% | Buy | +30.8% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $12.50+4.2% | Buy | +25.8% | Upgrade | 09.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $13.00+4.0% | Buy | +30.8% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 → $13.00+4.0% | Buy | +30.8% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $12.50+8.7% | Buy | +25.8% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $12.50+8.7% | Buy | +25.8% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.00 → $12.00+9.1% | Buy | +20.7% | Upgrade | 07.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $11.50+9.5% | Hold | +15.7% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.50 → $12.50+8.7% | Buy | +25.8% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.50 → $12.50+8.7% | Buy | +25.8% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $11.00−4.3% | Buy | +10.7% | Upgrade | 05.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $10.50−4.5% | Hold | +5.6% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.50−4.2% | Buy | +15.7% | Reiterated | 05.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 → $12.00−7.7% | Buy | +20.7% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 → $11.50−8.0% | Buy | +15.7% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 → $11.50−8.0% | Buy | +15.7% | Upgrade | 03.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $11.00−4.3% | Hold | +10.7% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 → $12.00−7.7% | Buy | +20.7% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $12.00−7.7% | Buy | +20.7% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 30.09.26on TipRanks 12:55 | −3.1%next day −7.4% · 5 days −0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 | Buy | +30.8% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 | Buy | +25.8% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 | Buy | +25.8% | Upgrade | 29.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 | Hold | +15.7% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 | Buy | +30.8% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 | Buy | +30.8% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $26.00 | Buy | +161.6% | Reiterated | 21.09.26on TipRanks 13:55 | −1.0%next day −0.8% · 5 days −2.2% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $20.00 | Buy | +101.2% | Reiterated | 11.08.26on TipRanks Aug 12 07:20 | −0.9%next day +0.6% · 5 days +2.4% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $35.00 | Buy | +252.1% | Reiterated | 06.08.26on TipRanks Aug 7 17:05 | +13.0%next day −3.3% · 5 days −7.1% | ↗ |
| Eddie Hickman★★★★★★★★★★#1243 · hits 64% · avg +28.1% | Guggenheim | $24.00 → $23.00−4.2% | Buy | +131.4% | Reiterated | 06.08.26on TipRanks Aug 7 07:50 | +13.0%next day −3.3% · 5 days −7.1% | ↗ |
| Jonathan Aschoff★★★★★★★★★★#12373 · hits 29% · avg −21.0% | Roth MKM | $21.00 | Buy | +111.3% | Reiterated | 06.08.26on TipRanks 15:05 | +13.0%next day −3.3% · 5 days −7.1% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $25.00 → $28.00+12.0% | Buy | +181.7% | Reiterated | 06.08.26on TipRanks 05:55 | +13.0%next day −3.3% · 5 days −7.1% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $25.00 | Buy | +151.5% | Reiterated | 05.08.26on TipRanks Aug 7 04:15 | +0.3%next day +13.0% · 5 days +8.3% | ↗ |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | $24.00 | Buy | +141.4% | Reiterated | 05.08.26on TipRanks Aug 6 06:05 | +0.3%next day +13.0% · 5 days +8.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Zevra Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.25 at a price of $10.97 (+130.2%); now: $25.25 at $9.94 (+154.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 16 | 21 | 25 | 17 | 11 |
| Buy | 3 | 3 | 4 | 4 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.16 (from $0.11 to $0.21). Last quarter: $0.14.
Sales
Next quarter’s sales estimate — $37M (from $35M to $41M). Last quarter: $40M.
Best top-analyst consensus in the sector · Healthcare
About Zevra Therapeutics
- CEO: Neil F. McFarlane
- Employees: 61
- 101 Federal Street, Boston, MA, 02110, US
- zevra.com
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Data from the stock’s TipRanks forecast page, read 74 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗